NCT06547736 - Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions

Pancreatic Cancer

Interventions

DRUG

SHR-A2102 or/and HRS-4642

"Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."

DRUG

SHR-A1904 or/and HRS-4642

"Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."

DRUG

SHR-A1811 or/and HRS-4642

"Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."

Trial Locations (1)

200032

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Fudan University

OTHER